A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.

Journal article

OBJECTIVE: Therapies with metformin, sulfonylureas, or insulin improve glycemic control in the short term but do not prevent progressive islet beta-cell failure or long-term deterioration in glycemia. Our goal was to evaluate, in patients recently diagnosed with type 2 diabetes (<3 years), the long-term efficacy of monotherapy with rosiglitazone on glycemic control and on the progression of pathophysiological abnormalities associated with type 2 diabetes as compared with metformin or glyb...

Expand abstract

Authors: Viberti, G; Kahn, SE; Greene, D; Herman, W; Zinman, B

• Publication status: Published
• Journal: Diabetes care
• Volume: 25
• Issue: 10
• Pages: 1737-1743
• Publication date: 2002-10-01
• DOI: 10.2337/diacare.25.10.1737
• EISSN: 1935-5548
• ISSN: 0149-5992
• Language: English
• Keywords: Treatment Outcome; Safety; Humans; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Disease Progression; Thiazoles; Thiazolidinediones; Treatment Failure; Research Design; Metformin; Blood Glucose; Glyburide; Time Factors; Albuminuria; Double-Blind Method